The trademark application STAR-CRISPR was filed by Celyntra Therapeutics SA, a corporation established under the laws of the Kingdom of Belgium (the "Applicant"). Application under examination.
The application was filed in Dutch (English was selected as the second language).
Goods And Services
The mark was filed in class 1 with following description of goods:
Reagents for research purposes
Reagents used in science
Reagents for scientific purposes
Reagents for medical research
Laboratory reagents for scientific use
Chemical reagents for scientific purposes
Reagents for scientific or medical research use
Chemical reagents for use in genetic research
Chemical reagents for use in biotechnology, other than for medical or veterinary use
Specialized reagents for genome editing for scientific, research, and laboratory use
Modified cells, in particular genetically modified iPS (induced pluripotent stem) cells and differentiated cells derived therefrom, for research or scientific purposes
Cell cultures, cell culture systems and cryopreserved genetically modified iPS cells for scientific and industrial research purposes
Cell cultures, and cryopreserved cells iPS cells other than for medical or veterinary use
Compositions and materials for scientific use, including cell culture agents for use in the biotechnology industry and cell material for use in combination with human cells, including genetically modified iPS or differentiated stem cells.
The mark was filed in class 5 with following description of goods:
Medical diagnostic reagents
Clinical medical reagents
Clinical diagnostic reagents
Reagents for use in medical genetic testing
Cells for medical use
Genetic identity tests comprised of reagents for medical purposes
Specialized reagents for genome editing for medical and medical clinical use
Modified cells, in particular genetically modified iPS (induced pluripotent stem) cells or differentiated cells derived therefrom, for medical or veterinary use
Cell cultures and cell culture systems, and cryopreserved pluripotent stem cells for medical or veterinary use
Genetically modified iPS (induced pluripotent stem) cells for use in generating other cells for therapeutic purposes
Cell cultures and cell culture systems, and cryopreserved genetically modified pluripotent stem cells for sub cultivation of cells.
The mark was filed in class 40 with following description of goods:
Custom manufacturing of iPS derived cells, and iPS derived cell therapy and manufacturing processes for others, including manufacturing in GMP-based facilities
Custom manufacture of therapeutic cells, medicines, cell therapies and gene edited cell therapies for others, including manufacturing in GMP-based facilities
Custom manufacture of cellular therapies, including manufacturing in GMP-based facilities
Manufacturing of cell lines (modified cells with specific genetic edits) for use in generating other cells.
The mark was filed in class 42 with following description of goods:
Structural and functional analysis of genomes
Research and development in the field of microorganisms and cells
Research in the field of gene editing technology
Genetic research
Gene therapy research
Scientific research in the field of genetics and genetic engineering
Research in the field of gene therapy
Research in the field of genetic diseases
Scientific research relating to genetics
Biotechnology research
Biotechnology testing
Preparation of reports in the biotechnology field
Research and testing of cell-based products, in particular therapeutic products
Research, optimization and testing of cell production processes
Laboratory research in the field of biotechnology using genetically modified iPS (induced pluripotent stem) cells or differentiated cells derived therefrom
Scientific research, design and development of scientific cell culture, cell therapy or gene edited cell therapy
Scientific research, design and development of cell culture, cell therapy or gene edited cell therapy, manufacturing systems and manufacturing processes for others
Platform as a service [Paas] in the field of cell therapy, and cell therapy development
Providing temporary use of a technological platform for the manufacturing of cell-based therapies, including technology, processes, and data analytics capabilities for process optimization and quality control.